ImageneBio Q2 FY26 net loss narrows to $10.2 million; R&D expenses rise to $6.7 million
IMA•Clinical programs continue
The Phase 2b ADAPTIVE atopic dermatitis trial continued under an amended protocol, with topline data expected in Q4 2027.
An independent monitoring committee backed the study continuing unchanged; a Phase 2 alopecia areata trial is planned to start in 2026.
Cash runway extends into 2028
Cash, cash equivalents and marketable securities totaled $136.2 million at June 30, with funding expected into the first quarter of 2028.
Quarterly loss narrows as expenses rise
ImageneBio posted a net loss of $10.2 million, or $0.63 per share, for the quarter ended June 30, 2026.
R&D expenses rose 17.54% to $6.7 million; G&A costs more than doubled to $5.1 million.
